Effect of rivoceranib administered as 200 mg once daily on the pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates

被引：0
|
作者：
Jang, Seong
Wei, Xiaohui
Meng, Xianzhang
Reitano, Joseph
Urity, Vinoo
Park, Cheol Hee
Strickland, Bill
Lee, Grace
Nguyen, David
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT131
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SIMULTANEOUS EVALUATION OF CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP1A2 HYDROXYLATION CAPACITY IN HUMANS
    De Andres, F.
    Paulmichl, M.
    Llerena, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
  • [2] Suppression of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activity by a cocktail of inflammatory cytokines
    Foster, John
    Webber, Guy
    Ormsby, Terry
    Cheung, Yen-Ling
    Paul, Danny S.
    Webber, Colin
    Waring, Adrian
    DRUG METABOLISM REVIEWS, 2016, 48 : 89 - 89
  • [3] Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
    Fernando de Andrés
    Catalina Altamirano-Tinoco
    Ronald Ramírez-Roa
    Carlos F Montes-Mondragón
    Pedro Dorado
    Eva M. Peñas-Lledó
    Adrián LLerena
    The Pharmacogenomics Journal, 2021, 21 : 140 - 151
  • [4] Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer
    Turner, P. Kellie
    Hall, Stephen D.
    Chapman, Sonya C.
    Rehmel, Jessica L.
    Royalty, Jane E.
    Guo, Yingying
    Kulanthaivel, Palaniappan
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (09) : 796 - 803
  • [5] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Lu, Sijie
    Nand, R. A.
    Yang, J. S.
    Chen, Gang
    Gross, A. S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 285 - 296
  • [6] Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Kirchheiner, J
    Müller, G
    Meineke, I
    Wernecke, KD
    Roots, I
    Brockmöller, J
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (05) : 459 - 466
  • [7] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Sijie Lu
    R. A. Nand
    J. S. Yang
    Gang Chen
    A. S. Gross
    European Journal of Clinical Pharmacology, 2018, 74 : 285 - 296
  • [8] The effects of buffer composition on the catalytic activities of human CYP1A2, CYP2C9, CYP2D6, and CYP3A4
    Gillespie, JS
    Binkley, SN
    Ring, BJ
    Wrighton, SA
    FASEB JOURNAL, 1998, 12 (04): : A144 - A144
  • [9] Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population
    Shi, Yan
    Xiang, Ping
    Li, Li
    Shen, Min
    FORENSIC SCIENCE INTERNATIONAL, 2011, 207 (1-3) : 183 - 187
  • [10] Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes
    Lim, HK
    Duczak, N
    Brougham, L
    Elliot, M
    Patel, K
    Chan, K
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (08) : 1211 - 1219
12345